Breaking News, Financial News

Financial Report: BASi

Consolidation efforts impact results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BASi 2Q Revenues: $5.2 million (-26%) 2Q Loss: $169,000 (loss of $1.9 million 2Q12) YTD Revenues: $11.0 million (-24%) YTD Loss: $30,000 (loss of $3.4 million YTD12) Comments: Service revenue in the quarter was down 31% due to the consolidation of BASi’s Oregon lab into its West Lafayette facility and the closure of its UK lab. Product revenue was down 12% in the quarter, primarily due to the delayed launch of Culex NxT, but increased 31% compared to 1Q13....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters